SciClone Pharmaceuticals, Inc.
Nov 8, 2011
PDF

SciClone Reports Financial Results for the Third Quarter of 2011

FOSTER CITY, CA -- (MARKET WIRE) -- 11/08/11 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the third quarter of 2011. Revenues for the quarter were $37.4 million compared to $22.8 million for the same period last year, an increase of $14.6 million. For the nine months ended September 30, 2011, revenues were $92.2 million, compared with $61.5 million last year, an increase of $30.7 million. The increase in revenues in the third quarter and year to date was due to the continued growth of the ZADAXIN® business in China and the inclusion of the NovaMed Pharmaceuticals, Inc. revenues since the date of the acquisition on April 18, 2011.

On a pro forma basis, assuming NovaMed had been acquired on January 1, 2010, revenues for the quarter were $37.4 million compared to $31.2 million for the same period last year, an increase of $6.2 million. For the nine months ended September 30, 2011, revenues were $100.2 million, compared with $83.5 million last year, an increase of $16.7 million on a pro forma basis.

"Our strategy of creating a market-leading specialty pharmaceutical company in China is progressing well as we continued to grow our top and bottom line in the third quarter," commented Friedhelm Blobel, Ph.D., SciClone President and Chief Executive Officer. "Our acquisition of NovaMed earlier this year significantly expanded our product portfolio and operational as well as sales and marketing capabilities in China. We believe that SciClone will be a partner of choice for many mid-sized Western pharmaceutical and biotechnology companies looking to commercialize their products in China. We look forward to further growing sales of ZADAXIN and our other lead products as we plan to increase our foothold in the Chinese market."

On a GAAP basis, SciClone's net income for the third quarter of 2011 was $10.2 million compared with $7.6 million for the same period last year, or $0.18 per share on a basic and $0.17 per share on a diluted basis for the three months ended September 30, 2011, compared with $0.16 per share on a basic and diluted basis for the same period last year. For the nine months ended September 30, 2011, SciClone reported net income of $16.1 million, or $0.30 per share on a basic and $0.28 per share on a diluted basis, compared with net income of $17.3 million, or $0.36 on a basic and $0.35 on a diluted basis for the same period last year.

SciClone's non-GAAP net income for the third quarter of 2011 was $9.8 million compared with non-GAAP income of $8.4 million for the same period of last year. For the nine months ended September 30, 2011, non-GAAP net income was $22.2 million, compared with non-GAAP net income of $19.1 million for the same period last year.

For the nine months and for the quarter ending September 30, 2011, the number of shares of common stock used in computing basic and diluted earnings per share increased significantly due to the 8.3 million shares issued in the acquisition of NovaMed in the second quarter and by approximately 2.2 million shares as a result of the stock option exercises this year. Non-GAAP earnings per share were $0.17 on a basic and $0.16 on a diluted basis for the third quarter of 2011, and $0.18 on a basic and $0.17 on a diluted basis, for the same period last year. For the nine months ended September 30, 2011, non-GAAP earnings per share were $0.41 per share on a basic and $0.39 on a diluted basis, compared with $0.40 on a basic and $0.39 on a diluted basis, for the same period last year.

SciClone believes this non-GAAP information is useful for investors by offering them the ability to better understand how management evaluates the business. The non-GAAP calculations and reconciliation to comparable GAAP measures were derived principally as a result of the NovaMed acquisition and is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Income."

Research and development expenses for the third quarter of 2011 totaled $3.0 million, compared with $2.6 million for the same period last year. For the nine months ended September 30, 2011, research and development expenses were $9.2 million, compared with $7.7 million for the same period last year. The increase was primarily related to the Company's SCV-07 phase 2b trial in oral mucositis and the addition of NovaMed research and development expenses since the date of the acquisition in April 2011.

Sales and marketing expenses for the third quarter of 2011 were $15.2 million, compared with $5.4 million for the same period last year. The increase of $9.8 million was primarily a result of the addition of approximately 450 sales and marketing employees through the acquisition of NovaMed earlier this year which significantly expanded SciClone's sales and marketing capabilities, as well as the expanded sales efforts for SciClone's lead product ZADAXIN. The Company now has a combined sales organization comprised of over 680 professionals in China. For the nine months ended September 30, 2011, sales and marketing expenses were $33.3 million compared with $16.0 million for the same period last year.

General and administrative expenses for the third quarter of 2011 were $5.2 million compared with $3.8 million for the same period last year. The increase was primarily related to the general and administrative expenses attributable to NovaMed operations, and higher professional services fees related to the Company's FCPA compliance efforts and various tax planning and compliance matters. For the nine months ended September 30, 2011, general and administrative expenses were $19.4 million, compared with $10.4 million for the same period last year.

At September 30, 2011, cash, cash equivalents and investments totaled $45.0 million, compared with $56.5 million at December 31, 2010. The decrease in SciClone's cash balance is primarily due to the $24.6 million consideration paid in the second quarter as part of the acquisition of NovaMed on April 18, 2011 partially offset by the cash generated by the Company's commercial operations. Accounts receivables were $50.5 million, an increase of $19.8 million compared to December 31, 2010, mainly due to timing of collections related to increased sales volumes and expected fluctuations in the timing of customer receipts.

Third Quarter 2011 Pipeline and Business Updates
In October, SciClone announced that its Board of Directors approved a share repurchase program authorizing the Company to repurchase up to $20 million of its outstanding common stock over 24 months. Under the program, purchases may be made from time to time in the open market, in privately negotiated transactions, or otherwise, at times and in amounts as the Company deems appropriate.

Third Quarter Conference Call
SciClone is hosting a conference call today at 8:30 am ET to provide a financial update. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, Gary Titus, Senior Vice President and CFO.

LIVE CALL:
877-556-5921 (U.S./Canada)
617-597-5474 (International)
Passcode: 45149576

REPLAY:
888-286-8010 (U.S./Canada)
617-801-6888 (International)
Passcode: 50188621
(Replay available from Tuesday, November 8, 2011, at 11:30 am ET until 11:59 pm ET on Tuesday, November 15, 2011)

The conference call will contain forward-looking statements. Interested parties who wish to listen to the webcast should visit the Investor Relations section of SciClone's website at www.sciclone.com. The information provided on the teleconference is accurate only at the time of the conference call, and SciClone will take no responsibility for providing updated information except as required by law.

About SciClone
SciClone Pharmaceuticals is a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone's ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the local regulatory approvals. Besides ZADAXIN, SciClone markets nearly 20 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also developing SCV-07 in a phase 2b trial for the delay to onset of oral mucositis in patients with head and neck cancer. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit www.sciclone.com.

Forward-Looking Statements
This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risk and uncertainties relating to: the course, cost and outcome of regulatory matters, including pricing decisions by authorities in China; the on-going regulatory investigations and SciClone's independent investigation; the Company's ability to execute on its goals in China and on its objectives for revenue in fiscal 2011; the challenges presented by integrating an acquired business into existing operations; the variability in earnings on a GAAP basis that may result from non-cash charges related to the NovaMed acquisition; the dependence on third party license, promotion or distribution agreements including the need to renew such agreements; operating an international business; the clinical trial process, including the regulatory approval and the process of initiating trials at, and enrolling patients at, clinical sites; the Company's ability to remediate its identified material weaknesses over internal control; and changes in its practices and policies which could adversely affect its ability to generate revenue. SciClone cannot predict the timing or outcome of the SEC and DOJ investigations, of the various litigations that have or may be filed relating to any of those matters, or of its efforts to cooperate with those investigations, however the Company expects to incur substantial expenses in connection with the investigations and the results of the investigations could include fines and further changes in its internal control or other remediation measures that could adversely affect its business. Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.

Ambien, Depakine, Stilnox and Tritace are registered trademarks of Sanofi.

Aggrastat is a registered trademark of Merck & Co., Inc.

DC Bead® is a registered trademark of Biocompatibles UK Limited.




                       SCICLONE PHARMACEUTICALS, INC.

              UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

                  (in thousands, except per share amounts)



                            Three months ended         Nine months ended

                               September 30,             September 30,

                         ------------------------  ------------------------

                             2011         2010         2011         2010

                         -----------  -----------  -----------  -----------



Revenues:

  Product sales          $    30,433  $    22,840  $    79,484  $    61,496

  Promotion services           6,992            -       12,711            -

                         -----------  -----------  -----------  -----------

    Total revenues            37,425       22,840       92,195       61,496



Operating expenses:

  Cost of product sales        5,024        3,146       13,301        9,445

  Sales and marketing         15,222        5,445       33,311       15,996

  Amortization of

   acquired intangible

   assets, related to

   sales and marketing           858            -        1,572            -

  Research and

   development                 3,035        2,618        9,235        7,700

  General and

   administrative              5,202        3,820       19,419       10,403

  Contingent

   consideration              (2,231)           -       (1,423)           -

                         -----------  -----------  -----------  -----------

    Total operating

     expenses                 27,110       15,029       75,415       43,544

                         -----------  -----------  -----------  -----------



Income from operations        10,315        7,811       16,780       17,952



Interest and investment

 income                           15           31           48           79

Interest and investment

 expense                         (49)         (19)        (159)         (57)

Other (expense) income,

 net                              (5)          64            6          (19)

                         -----------  -----------  -----------  -----------

Income before provision

 for income tax               10,276        7,887       16,675       17,955

Provision for income tax          46          259          613          654

                         -----------  -----------  -----------  -----------

Net income               $    10,230  $     7,628  $    16,062  $    17,301

                         ===========  ===========  ===========  ===========



Basic net income per

 share                   $      0.18  $      0.16  $      0.30  $      0.36

Diluted net income per

 share                   $      0.17  $      0.16  $      0.28  $      0.35



Weighted average shares

 used in computing:

  Basic net income per

   share                      58,331       47,795       54,044       47,535

  Diluted net income per

   share                      60,437       49,071       56,426       49,293







                       SCICLONE PHARMACEUTICALS, INC.

                RECONCILIATION OF GAAP TO NON-GAAP NET INCOME

                  (in thousands, except per share amounts)

                                 (unaudited)



                             Three months ended        Nine months ended

                             September 30, 2011        September 30, 2011

                         ------------------------- -------------------------

                             2011         2010         2011         2010

                         -----------  ------------ -----------  ------------



GAAP net income          $    10,230  $      7,628 $    16,062  $     17,301

Non-GAAP adjustments:

  Employee stock-based

   compensation                  881           547       2,130         1,552

  Contingent

   consideration              (2,231)            -      (1,423)            -

  Amortization of

   acquired intangible

   assets                        858             -       1,572             -

  Acquisition related

   costs                          28           250       3,810           250

                         -----------  ------------ -----------  ------------

    Non-GAAP net income  $     9,766  $      8,425 $    22,151  $     19,103

                         -----------  ------------ -----------  ------------





Non-GAAP basic net

 income per share        $      0.17  $       0.18 $      0.41  $       0.40

Non-GAAP diluted net

 income per share        $      0.16  $       0.17 $      0.39  $       0.39



Weighted average shares

 used in computing:

GAAP and Non-GAAP basic

 net income per share         58,331        47,795      54,044        47,535

GAAP and Non-GAAP

 diluted net income per

 share                        60,437        49,071      56,426        49,293





SciClone management uses these non-GAAP financial measures to monitor and evaluate the Company's operating results and trends on an on-going basis and internally for operations, budgeting and financial planning purposes. SciClone believes the non-GAAP information is useful for investors by offering them the ability to better understand how management evaluates the business. These non-GAAP measures have limitations, however, because they do not include all items of income and expenses that affect SciClone. These non-GAAP financial measures that management uses are not prepared in accordance with, and should not be considered in isolation of, or as an alternative to, measurements required by GAAP.

SciClone's non-GAAP financial measures exclude the following items from GAAP net income and net income per share:




                       SCICLONE PHARMACEUTICALS, INC.

                    UNAUDITED SELECTED BALANCE SHEET DATA

                               (in thousands)





                                                September 30,  December 31,

                                                    2011           2010

                                               -------------- --------------



Cash and investments                           $       44,951 $       56,522

Accounts receivable, net                               50,491         30,671

Inventories                                             9,141          7,078

Intangible assets, net                                 45,562              -

Goodwill                                               31,569              -

Total assets                                          186,690         97,807

Total current liabilities                              18,336         12,129

Liability for contingent consideration                 17,433              -

Deferred tax liability                                  8,472              -

Long-term borrowing on line of credit                   2,500          2,500

Total shareholders' equity                            139,415         82,188





Corporate Contacts

Gary Titus

Chief Financial Officer

650.358.3456

gtitus@sciclone.com



Ana Kapor

Investors/Media

650.350.4825

akapor@sciclone.com



Source: SciClone Pharmaceuticals, Inc.

News Provided by Acquire Media